Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 162 of the 167 references it cites were found in a registry or an index; 110 of the 165 sources its claims cite were checked for support.

Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis

Open access

Abstract

The innovative development of nanomedicine has promised effective treatment options compared to the standard therapeutics for cancer therapy. However, the efficiency of EPR-targeted nanodrugs is not always pleasing as it is strongly prejudiced by the heterogeneity of the enhanced permeability and retention effect (EPR). Targeting the dynamics of the EPR effect and improvement of the therapeutic effects of nanotherapeutics by using EPR enhancers is a vital approach to developing cancer therapy. Inadequate data on the efficacy of EPR in humans hampers the clinical translation of cancer drugs. Molecular targeting, physical amendment, or physiological renovation of the tumor microenvironment (TME) are crucial approaches for improving the EPR effect. Advanced imaging technologies for the visualization of EPR-induced nanomedicine distribution in tumors, and the use of better animal models, are necessary to enhance the EPR effect. This review discusses strategies to enhance EPR effect-based drug delivery approaches for cancer therapy and imaging technologies for the diagnosis of EPR effects. The effort of studying the EPR effect is beneficial, as some of the advanced nanomedicine-based EPR-enhancing approaches are currently undergoing clinical trials, which may be helpful to improve EPR-induced drug delivery and translation to clinics.

Overview

CoChat Summary

## TL;DR

This review argues that EPR-based nanodrug delivery is promising but highly variable in humans because tumor vasculature, extracellular matrix, and the tumor microenvironment are heterogeneous. It surveys pharmacological, physical, and imaging-based strategies to improve EPR and emphasizes that personalized, model-appropriate, multimodal approaches are needed for clinical translation.

## Key findings

  • The paper identifies two broad classes of EPR-enhancing strategies: pharmacological approaches that alter the tumor microenvironment, and physical approaches using external stimuli such as heat, radiation, photodynamic therapy, and ultrasound.
  • It reports several quantitative examples from prior studies: tissue plasminogen activator pretreatment increased penetration of 115 nm nanoparticles in A549 xenograft mice; DC101 plus chemotherapy produced an approximately threefold accumulation increase of smaller nanoparticles; a cediranib plus size-changeable gold nanoparticle strategy produced about a twofold increase in tumor size suppression; liposomal doxorubicin plus NaHCO3 increased drug uptake by 21-fold in a TNBC mouse model.
  • The review cites literature estimating that only 0.7% of systemically administered nanoparticles reach tumors, and that only 0.1% to 0.2% of the injected dose is effective against tumor cells with significant anticancer effects.
  • It highlights a major controversy: one cited study found that around 97% of nanoparticles may enter tumors via active transcytosis rather than passive transport through endothelial gaps.

## Methods

  • This is a narrative review of published work on EPR-based drug delivery for cancer therapy and diagnosis, organized around strategies to enhance EPR, tumor microenvironment targeting, imaging, challenges, and clinical translation.
  • The paper synthesizes evidence from preclinical animal models, some clinical studies, and imaging studies, and discusses specific examples of nanoparticles, drugs, and EPR enhancers reported in the literature.
  • Its main analysis is comparative and conceptual rather than experimental: it classifies strategies, summarizes reported outcomes, and argues for multimodal imaging and better animal models to evaluate EPR more accurately.

## Limitations

  • The paper explicitly states that data on the efficacy of EPR in humans are inadequate, which hampers clinical translation.
  • It also states that EPR is highly heterogeneous across tumor types, sizes, sites, and patients, so one-size-fits-all approaches are inadequate.
  • Evident from the text: the paper is a review and does not present original experimental data, so its conclusions depend on the quality and consistency of the cited studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/jpm13030389

Cites

162 of 162 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Pharmacological approaches to improve EPR effect. (A). Vascular normalizer to improve the blood flow, (B). Fibrinolytics co-therapy, (C). Enhanced permeability of endothelial cells using vascular mediators, (D). Stromal density decreases by ECM degradation, (E). Tumor-penetrating peptides enhance transcytosis. Reprinted with permission from [23]. Copyright (2023), with permission from Elsevier.
Figure 1 Pharmacological approaches to improve EPR effect. (A). Vascular normalizer to improve the blood flow, (B). Fibrinolytics co-therapy, (C). Enhanced permeability of endothelial cells using vascular mediators, (D). Stromal density decreases by ECM degradation, (E). Tumor-penetrating peptides enhance transcytosis. Reprinted with permission from [23]. Copyright (2023), with permission from Elsevier.CC BY · PubMed Central
Figure 2 Strategies to enhance EPR-based drug delivery targeting the tumor microenvironment. Adapted with permission from [17].
Figure 2 Strategies to enhance EPR-based drug delivery targeting the tumor microenvironment. Adapted with permission from [17].CC BY · PubMed Central
Figure 3 Imaging NP pharmacology and the EPR effect across multiple spatial and temporal scales. (A) Pharmacokinetics and pharmacodynamics (PK/PD) of NPs (B). Imaging strategies and (C) IVM modalities are particularly suitable for imagining dynamic and microscopic courses of the EPR effect and the TME. Adapted with permission from [18].
Figure 3 Imaging NP pharmacology and the EPR effect across multiple spatial and temporal scales. (A) Pharmacokinetics and pharmacodynamics (PK/PD) of NPs (B). Imaging strategies and (C) IVM modalities are particularly suitable for imagining dynamic and microscopic courses of the EPR effect and the TME. Adapted with permission from [18].CC BY · PubMed Central

Verification

Claims the paper makes

76 Valid · 10 Not valid · 36 Not checked · 33 Own results and interpretations

88 more claims · 56 with their cited sources checked

Create a free account to see all 155 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 43
  • Probably not a substantial claim. 25

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 167 references

Research works printed but not linked: 1

  1. Yin, 2014, Enhanced Permeability and Retention (EPR) Effect Based Tumor Targeting: The Concept, Application and Prospect, JSM Clin. Oncol. Res., 2, 1010

Cited by

See all 98

Metadata

Authors
Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P.
Affiliations
  • Shahjalal University of Science and Technology (BD)
  • Northeastern University (US)
Corresponding author
  • Subhan, Md Abdus
  • Torchilin, Vladimir P.
Venue
Journal of Personalized Medicine
Publisher
MDPI AG
Published
2023-02-23
Volume
13
Issue
3
Pages
389
ISSN
2075-4426 (ISSN-L)
OpenAlex
W4321601715
Cited by
98
References
167
Citations by year
2026: 34 · 2025: 33 · 2024: 26 · 2023: 5
FWCI
1.72
Type
journal article
Language
en
Open access
Locations
  • Journal of Personalized Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
Keywords
enhanced permeability and retention effect, tumor microenvironment, nanomedicine, anticancer drug delivery, tumor targeting, tumor imaging, animal models, clinical translation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis. https://app.cochat.ai/papers/10.3390/jpm13030389
The paper
Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P. (2023). Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis. Journal of Personalized Medicine. https://doi.org/10.3390/jpm13030389

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.